Related Experiment Videos

XIAP Interacts with and Regulates the Activity of FAF1

Marcos J Caballero-López1, Manuel Nieto-Díaz1, Mónica Yunta2

  • 1Molecular Neuroprotection Laboratory, Hospital Nacional de Parapléjicos, SESCAM, Toledo, Spain.

Insights

The X-linked inhibitor of apoptosis protein (XIAP) interacts with Fas-associated factor 1 (FAF1), a pro-apoptotic factor. XIAP blocks FAF1-induced cell death and regulates NF-κB signaling, offering therapeutic insights.

Area of Science:

  • Cellular biology
  • Molecular mechanisms of cell death
  • Apoptosis and cell survival signaling

Background:

  • Cell death is regulated by the balance of pro- and anti-apoptotic factors.
  • X-linked inhibitor of apoptosis protein (XIAP) is a key anti-apoptotic factor inhibiting caspases and regulating survival pathways.
  • Fas-associated factor 1 (FAF1) is a pro-apoptotic factor involved in similar signaling pathways to XIAP.

Purpose of the Study:

  • To investigate the functional relationship between XIAP and FAF1.
  • To identify the interaction between XIAP and FAF1.
  • To elucidate their opposing roles in cell death and NF-κB signaling.

Main Methods:

  • Protein-protein interaction studies to identify and map the XIAP-FAF1 interaction.
  • Caspase cascade activity assays.
  • NF-κB pathway activation and inhibition assays.
  • Ubiquitination assays.

Main Results:

  • Demonstrated a direct interaction between XIAP and FAF1, defining the specific interaction regions.
  • XIAP inhibits FAF1-mediated cell death by interfering with the caspase cascade.
  • XIAP blocks FAF1's inhibition of the NF-κB pathway.
  • XIAP promotes FAF1 ubiquitination.
  • FAF1 binding to XIAP's BIR domains does not impede XIAP's anti-apoptotic function but attenuates XIAP-mediated NF-κB activation.

Conclusions:

  • XIAP and FAF1 interact, with XIAP acting as a negative regulator of FAF1's pro-apoptotic functions.
  • The balance between XIAP and FAF1 influences cell death and NF-κB signaling.
  • Understanding this interplay is crucial for developing therapies for degenerative diseases and cancer.

Related Concept Videos